Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

Fig. 2

a Kaplan–Meier curves for time to first subsequent therapy (TFST) and b overall survival (OS) in patients who received an etoposide/platinum (EP)- or irinotecan/platinum (IP)-based concurrent chemoradiotherapy regimen as definite treatment for limited-disease small-cell lung cancer. TFST, time to first subsequent therapy; EP, etoposide/platinum; IP, irinotecan/platinum CCRT, concurrent chemoradiotherapy; CI, confidence interval

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us